Igm Biosciences Stock Fundamentals
| IGMS Stock | USD 9.40 0.51 5.74% |
IGM Biosciences fundamentals help investors to digest information that contributes to IGM Biosciences' financial success or failures. It also enables traders to predict the movement of IGM Stock. The fundamental analysis module provides a way to measure IGM Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to IGM Biosciences stock.
At this time, IGM Biosciences' Total Other Income Expense Net is comparatively stable compared to the past year. Income Tax Expense is likely to gain to about 711.9 K in 2024, despite the fact that Gross Profit is likely to grow to (201.1 M). IGM | Select Account or Indicator |
IGM Biosciences Company Operating Margin Analysis
IGM Biosciences' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current IGM Biosciences Operating Margin | (124.78) % |
Most of IGM Biosciences' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, IGM Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, IGM Biosciences has an Operating Margin of -124.781%. This is 255.7% higher than that of the Biotechnology sector and 11.34% higher than that of the Health Care industry. The operating margin for all United States stocks is notably higher than that of the company.
IGM Biosciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining IGM Biosciences's current stock value. Our valuation model uses many indicators to compare IGM Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across IGM Biosciences competition to find correlations between indicators driving IGM Biosciences's intrinsic value. More Info.IGM Biosciences is rated second overall in return on equity category among its peers. It is rated fourth overall in return on asset category among its peers . At this time, IGM Biosciences' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value IGM Biosciences by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.IGM Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses IGM Biosciences' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of IGM Biosciences could also be used in its relative valuation, which is a method of valuing IGM Biosciences by comparing valuation metrics of similar companies.IGM Biosciences is currently under evaluation in operating margin category among its peers.
IGM Biosciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of IGM Biosciences from analyzing IGM Biosciences' financial statements. These drivers represent accounts that assess IGM Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of IGM Biosciences' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 343.3M | 2.7B | 982.0M | 706.7M | 434.7M | 594.6M | |
| Enterprise Value | 322.1M | 2.5B | 877.4M | 626.6M | 362.7M | 537.0M |
IGM Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, IGM Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to IGM Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
IGM Fundamentals
| Return On Equity | -1.32 | ||||
| Return On Asset | -0.37 | ||||
| Operating Margin | (124.78) % | ||||
| Current Valuation | 355.71 M | ||||
| Shares Outstanding | 34.08 M | ||||
| Shares Owned By Insiders | 35.04 % | ||||
| Shares Owned By Institutions | 63.98 % | ||||
| Number Of Shares Shorted | 3.37 M | ||||
| Price To Earning | (7.72) X | ||||
| Price To Book | 6.70 X | ||||
| Price To Sales | 191.56 X | ||||
| Revenue | 2.13 M | ||||
| Gross Profit | 1.07 M | ||||
| EBITDA | (253.36 M) | ||||
| Net Income | (246.42 M) | ||||
| Cash And Equivalents | 469.14 M | ||||
| Cash Per Share | 10.95 X | ||||
| Total Debt | 40.51 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 10.79 X | ||||
| Book Value Per Share | 1.33 X | ||||
| Cash Flow From Operations | (192.23 M) | ||||
| Short Ratio | 11.83 X | ||||
| Earnings Per Share | (3.61) X | ||||
| Target Price | 19.6 | ||||
| Number Of Employees | 198 | ||||
| Beta | 0.19 | ||||
| Market Capitalization | 558.96 M | ||||
| Total Asset | 423.41 M | ||||
| Retained Earnings | (821.24 M) | ||||
| Working Capital | 305.12 M | ||||
| Current Asset | 1.23 M | ||||
| Current Liabilities | 3.37 M | ||||
| Net Asset | 423.41 M |
About IGM Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze IGM Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of IGM Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of IGM Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 3.8 M | 3.6 M | |
| Total Revenue | 2.1 M | 2.2 M | |
| Cost Of Revenue | 213.8 M | 224.5 M | |
| Stock Based Compensation To Revenue | 21.85 | 35.02 | |
| Sales General And Administrative To Revenue | 23.51 | 38.52 | |
| Research And Ddevelopement To Revenue | 101.18 | 147.90 | |
| Capex To Revenue | 5.81 | 8.45 | |
| Revenue Per Share | 0.04 | 0.03 | |
| Ebit Per Revenue | (123.69) | (129.88) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for IGM Stock Analysis
When running IGM Biosciences' price analysis, check to measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.